Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency (EVELINE)
A Comparative Study to Assess the Efficacy and Safety of Endolex Forte vs Diosmin and Hesperidin in Reducing the symptomatoLogy of Patients With ChronIc VeNous Insufficiency Between Functional Classes CEAP 1-4, During a Period of 6 Months
Sponsor: Opera CRO, a TIGERMED Group Company
Listed as NCT02927483, this PHASE3 trial focuses on Chronic Venous Insufficiency and remains ongoing. Sponsored by Opera CRO, a TIGERMED Group Company, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Nov 2018 — Apr 2019 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Opera CRO, a TIGERMED Group Company
- SunWave Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.